- Home
- NAMS vs CPRX Comparison
NAMS vs CPRX Comparison
Compare NAMS & CPRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NAMS
- CPRX
- Stock Information
- Founded
- NAMS 2019
- CPRX 2002
- Country
- NAMS Netherlands
- CPRX United States
- Employees
- NAMS N/A
- CPRX N/A
- Industry
- NAMS Biotechnology: Pharmaceutical Preparations
- CPRX Biotechnology: Pharmaceutical Preparations
- Sector
- NAMS Health Care
- CPRX Health Care
- Exchange
- NAMS Nasdaq
- CPRX Nasdaq
- Market Cap
- NAMS 2.7B
- CPRX 2.6B
- IPO Year
- NAMS N/A
- CPRX 2006
- Fundamental
- Price
- NAMS $27.00
- CPRX $20.29
- Analyst Decision
- NAMS Strong Buy
- CPRX Strong Buy
- Analyst Count
- NAMS 10
- CPRX 5
- Target Price
- NAMS $41.40
- CPRX $33.20
- AVG Volume (30 Days)
- NAMS 872.1K
- CPRX 1.4M
- Earning Date
- NAMS 08-06-2025
- CPRX 11-05-2025
- Dividend Yield
- NAMS N/A
- CPRX N/A
- EPS Growth
- NAMS N/A
- CPRX 183.96
- EPS
- NAMS N/A
- CPRX 1.65
- Revenue
- NAMS $64,006,000.00
- CPRX $558,499,000.00
- Revenue This Year
- NAMS N/A
- CPRX $16.51
- Revenue Next Year
- NAMS N/A
- CPRX $9.58
- P/E Ratio
- NAMS N/A
- CPRX $12.29
- Revenue Growth
- NAMS 762.15
- CPRX 28.55
- 52 Week Low
- NAMS $14.06
- CPRX $19.00
- 52 Week High
- NAMS $27.29
- CPRX $26.58
- Technical
- Relative Strength Index (RSI)
- NAMS 67.63
- CPRX 47.06
- Support Level
- NAMS $24.41
- CPRX $19.17
- Resistance Level
- NAMS $25.65
- CPRX $21.19
- Average True Range (ATR)
- NAMS 1.10
- CPRX 0.72
- MACD
- NAMS 0.05
- CPRX 0.02
- Stochastic Oscillator
- NAMS 98.63
- CPRX 42.26
About NAMS NewAmsterdam Pharma Company N.V.
NewAmsterdam Pharma Co NV is a late-stage biopharmaceutical company with a mission to improve patient care in populations with metabolic diseases where currently approved therapies have not been adequate or well tolerated. Its product, obicetrapib, is a next-generation, oral, low-dose CETP inhibitor that is developed to potentially overcome the limitations of current LDL-C lowering treatments.
About CPRX Catalyst Pharmaceuticals Inc.
Catalyst Pharmaceuticals Inc is a biopharmaceutical company. It focuses on developing and commercializing, developing therapies for people with rare, debilitating, chronic neuromuscular and neurological diseases. It offers three drug products, FIRDAPSE (amifampridine), FYCOMPA (perampanel), and AGAMREE (vamorolone).